Drug shortage
Adalimumab-adaz Injection · Sandoz Inc.
FDA drug shortage · To Be Discontinued · updated Jan 13, 2026
Key facts
| Generic name | Adalimumab-adaz Injection |
|---|---|
| Company | Sandoz Inc. |
| Presentation | Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64) |
| Dosage form | Injection |
| Status | To Be Discontinued |
| Therapeutic category | Rheumatology |
| Package NDCs | 61314-473-64 |
| First posted | Jan 13, 2026 |
| Last updated | Jan 13, 2026 |
| Discontinued | Jan 13, 2026 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: